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Oliver Lee, MS,† Nithya Ramnath, MD,‡ Rishindra M. Reddy, MD,* Jules Lin, MD,*
Andrew C. Chang, MD,* Mark B. Orringer, MD,* and David G. Beer, PhD*
Introduction: This prospective study aimed to develop a robust and
clinically applicable method to identify patients with high-risk
early-stage lung cancer and then to validate this method for use in
future translational studies.
Methods: Three published Affymetrix microarray data sets repre-
senting 680 primary tumors were used in the survival-related gene
selection procedure using clustering, Cox model, and random sur-
vival forest analysis. A final set of 91 genes was selected and tested
as a predictor of survival using a quantitative real-time polymerase
chain reaction-based assay using an independent cohort of 101 lung
adenocarcinomas.
Results: The random survival forest model built from 91 genes in
the training set predicted patient survival in an independent cohort of
101 lung adenocarcinomas, with a prediction error rate of 26.6%.
The mortality risk index was significantly related to survival (Cox
model p  0.00001) and separated all patients into low-, medium-,
and high-risk groups (hazard ratio 1.00, 2.82, 4.42). The mortality
risk index was also related to survival in stage 1 patients (Cox model
p  0.001), separating patients into low-, medium-, and high-risk
groups (hazard ratio  1.00, 3.29, 3.77).
Conclusions: The development and validation of this robust quan-
titative real-time polymerase chain reaction platform allows predic-
tion of patient survival with early-stage lung cancer. Utilization will
now allow investigators to evaluate it prospectively by incorporation
into new clinical trials with the goal of personalized treatment of
patients with lung cancer and improving patient survival.
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Lung cancer is the leading cause of cancer-related death, andnon-small cell lung cancer (NSCLC) accounts for almost
80% of deaths from lung cancer.1 Surgery is the major treatment
option for patients with early-stage (stages IA and IB) NSCLC,
yet as many as 35 to 50% of these patients will relapse within 5
years, indicating that a “high-risk” subgroup of these patients
might benefit from adjuvant chemotherapy if properly identi-
fied.2 Although recent studies have demonstrated significantly
improved survival using adjuvant chemotherapy in patients
undergoing pulmonary resection for stage IB, II, or IIIA
NSCLC, these patients are subject to treatment-related toxic-
ity.2–5 It remains a critical and unsolved challenge to estimate
more precisely the risk for survival or recurrence in individual
patients to provide adjuvant therapy to high-risk patients and
avoid providing adjuvant therapy to low-risk patients.
The emerging use of gene expression signatures may
enable clinicians to make treatment decisions based on specific
characteristics of individual patients and their tumor. Many
microarray-based gene profiles with gene numbers varying from
dozens to thousands have been reported to predict patient sur-
vival in lung cancer.6–14 Because of the need for specialized
laboratory facilities, the large number of contributing genes, and
complex statistical analyses, microarray-based gene expression
profiles are not very practical for clinical use. Alternatively, a
quantitative real-time polymerase chain reaction (qRT-PCR)
method may be used more efficiently. Several qRT-PCR profiles
have been reported,15–22 but none of these gene sets have been
refined or tested adequately for clinical use.
In this study, we have combined microarray gene pro-
files of a large NSCLC data set8,12,13 and a qRT-PCR-based
approach, using a novel gene selection method. A novel
aspect of the design was to include genes representing diverse
biological processes and then to measure gene expression
using qRT-PCR. Finally, we developed and then verified a
91-gene qRT-PCR card-based platform survival classifier
using an independent cohort of 101 lung adenocarcinomas.
The strategy used in this study is shown in Figure 1. This
strategy was prospectively defined and executed as planned.
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PATIENTS AND METHODS
The methods are briefly described in this article with
full descriptions in the Supplementary Methods (Supplemen-
tal Digital Content 1, http://links.lww.com/JTO/A115).
Published Microarray Data Collection
Three published Affymetrix microarray data sets rep-
resenting 680 primary tumors were used in the survival-
related gene selection procedure. The primary training data
set included 439 lung adenocarcinomas from a consortia
study of four centers,13 and a combined 111 lung adenocar-
cinomas and squamous cell carcinoma (SCC) data set repre-
sented test set 18 and a 130 lung SCC data set was used as test
set 2.12 The clinical information for these three data sets is
provided in Table 1. Other microarray data sets7,9,10,14 were
not chosen due to platform differences, sample sizes less than
100, or not having survival information. Our primary out-
come was overall survival for all datasets censored at 5 years.
The information concerning adjuvant chemotherapy or radi-
ation therapy was provided in the original articles and also
summarized in Table 1.
Patients and Tissue Specimens for qRT-PCR
Measurements
A subset of 47 of the 439 patients had qRT-PCR
measured. In addition, we identified an independent valida-
tion set of 101 lung adenocarcinomas procured from patients
having pulmonary resection for cancer between February
1992 and November 2007 at the University of Michigan (a
total of 120 samples were examined using qRT-PCR, includ-
ing 12 paired normal lung and tumor tissues and 7 duplicate
tumor samples representing a different portion of these tu-
mors). This study was approved by the Institutional Review
Board of the University of Michigan. None of the patients
received preoperative chemotherapy or radiation therapy. A
total of 68 patients were stage 1b or above 1b, and 38 of these
68 patients (56%) received adjuvant chemotherapy or radia-
tion therapy. No adjuvant therapy was provided to the 29 of
33 stage 1a patients. The clinical information for this cohort
is presented in Table 1.
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FIGURE 1. Strategy for the development and validation of
the 91-gene quantitative real-time polymerase chain reaction
(qRT-PCR) classifier for lung cancer prognosis.
TABLE 1. Clinical Characteristics of Samples Used in this Study
Data Set Training Set Bild Test Set Raponi Test Set Validation Set
Platform U133A U133  2.0 U133A qRT-PCR
Sample number 439 111 130 101
Type of cancer AD 58 AD/53 SCC SCC AD
Age average (SD) 64.4 (10.1) 64.8 (9.6) 67.5 (9.9) 67.0 (9.6)
Gender
Female 218 (49.7%) 48 (43.2%) 48 (36.9%) 53 (52.5%)
Male 221 63 82 48
Stage
Stage I 276 (62.9%) 67 (63.2%) 73 (56.2%) 59 (58.4%)
Stage II 104 18 34 16
Stage III 59 21 23 26
Differentiation
Well 60 NA 15 28
Moderate 208 NA 76 38
Poor 166 (38.3%) NA 39 (30%) 34 (33.7%)
Dead (5 yr) 186 (42.4%) 58 (52.3%) 52 (40%) 44 (43.6%)
Alive 253 53 78 57
Median survival (mo) 47 31.1 34.5 28.8
Adjuvant therapy 108 Unknown 48 42
No adjuvant therapy 329 Unknown 69 58
AD, adenocarcinoma; SCC, squamous cell cancer; NA, not applicable.
Adjuvant therapy includes chemotherapy and/or radiotherapy. Unknown adjuvant therapy were 2, 13, and 1 for Training, Raponi, and
Validation sets, respectively.
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Custom TaqMan Low-Density Arrays and
qRT-PCR
Regions containing a minimum of 70% tumor cellular-
ity were used for RNA isolation. RNA quality was analyzed
by 2100 Bioanalyzer (Agilent Santa Clara, CA). Custom
TaqMan Low-Density Arrays (384-well micro fluidic cards)
were obtained from Applied Biosystems Inc. The primers of
survival-related genes including endogenous loading control
gene (18S RNA, beta-actin, and glyceraldehyde-3-phosphate
dehydrogenase) and blank controls were preapplied to the
cards. The preparation and running of the microfluidic cards
(qRT-PCR) followed the guidelines of the product protocols.
Cycle threshold values were generated for each card by
automatic selection of a threshold. The technical performance
and repeatability measures were tested (Supplementary Figures
S1–S3, Supplemental Digital Content 1, http://links.lww.com/
JTO/A115) before performing experiments using large numbers
of samples.
Statistical Analysis
Initial Microarray Data Processing and Filtering
The preprocessing and filtering steps were identical to
those described in Shedden et al.13 (Supplementary Methods,
Supplemental Digital Content 1, http://links.lww.com/JTO/
A115). After prescreening, 13,306 probes were left for fur-
ther analysis. All genes in training and testing datasets were
median-centered and the median absolute deviation (MAD)
scaled before use in subsequent analyses.
Preselection of Survival-Related Clusters and
Genes
The first step in the strategy was to select approxi-
mately 370 promising genes from the Affymetrix data. Using
the 439 training samples, genes were first separated into 300
groups using K-means clustering. A two-stage selection pro-
cedure was then implemented; first, selection of clusters and
second, selection of genes within each of the selected clus-
ters. The top 73 clusters whose cluster mean was most
associated with survival were selected using backward elim-
ination and stepwise regression using a Cox proportional
hazard model. Within each of the selected clusters, the second
selection identified a subset of genes prognostic for survival
based on a combination of various criteria, which are de-
scribed in Supplementary Methods (Supplemental Digital
Content 1, http://links.lww.com/JTO/A115). This approach
led to a set of 73 clusters and a total of 368 genes from the
selected clusters considered relevant to patient survival of
lung cancer. We also tested the survival predictability of
these 368 genes using two independent datasets (Bild et al.,
110 samples and Raponi et al., 130 samples) with random
survival forests (RSFs) (Supplementary Results, Supplemen-
tal Digital Content 1, http://links.lww.com/JTO/A115).
Normalization and Imputation of qRT-PCR Values
The second step in the strategy was to measure the
preselected 368 genes using qRT-PCR technology on a subset
of the 439 training samples. The qRT-PCR measurements on
the 47 samples were standardized using the control gene 18S
RNA. The qRT-PCR measurements on the remaining 392
patients were treated as missing data, and a multiple impu-
tation (MI) strategy was used to make full use of all 439
patients to build a prediction model. The MI was performed
using IVEware.23 The details of MI and alternative strategies of
normalizing the microarray data for the training set of 439
samples are described in the Supplementary Methods (Supple-
mental Digital Content 1, http://links.lww.com/JTO/A115). The
Spearman’s correlations between qRT-PCR and Affymetrix-
based measurements were calculated.
RSFs for Survival Analysis and Prediction
The third step of the strategy was to further refine the
selected genes down to approximately 91 genes for final evalu-
ation and validation using qRT-PCR measurements. The details
of RSF are described in the Supplementary Methods (Supple-
mental Digital Content 1, http://links.lww.com/JTO/A115).
To assess the statistical significance of the predictions
on the validation dataset, the mortality risk index (MRI) was
included as a continuous variable in a univariate Cox model
both for all 101 tumors and for stage 1 tumors only. Kaplan-
Meier survival analyses are shown using the MRI to separate
patients into three risk tertiles (high-, medium-, and low-risk,
one-third in each group).
RESULTS
Identification of a Survival-Related 91 Gene
Subset
To identify a 91-gene qRT-PCR platform-based classi-
fier obtained from a subset of the 368 genes selected in the
Affymetrix platform, three major criteria were considered:
correlation between Affymetrix and qRT-PCR, association of
gene with survival, and representation of a broad spectrum of
biological processes.
First, we defined genes whose qRT-PCR measurement
showed high correlation with Affymetrix microarray mea-
surements based on the same 47 samples used in the training
set. There were 301 of 368 (82%) genes, which had a
significantly high correlation value larger than 0.5 (p 
0.001, Table 2 and Supplementary Figure S5, Supplemental
Digital Content 1, http://links.lww.com/JTO/A115).
TABLE 2. Spearman Correlation Between qRT-PCR and
Affymetrix Microarray Data
Spearman Correlation No. of Genes
0.9 67
0.8–0.9 92
0.7–0.8 71
0.6–0.7 46
0.5–0.6 25
0.4–0.5 23
0.3–0.4 15
0.2–0.3 13
0.2 16
qRT-PCR, quantitative real-time polymerase chain reaction.
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Second, based on the Affymetrix expression values and
the measured qRT-PCR expression values, we imputed the
qRT-PCR values for the remaining patients in the training
dataset. We performed a RSF using 1000 trees and repeated
it 10 times on each of the 20 imputed training data sets. We
selected genes that had either: (a) p values from the Cox
model adjusted for stage and age on the imputed PCR data
which were less than 0.05 or (b) average variable importance
measure (VIMP) from the RSF (mean of 10 VIMPs per
dataset) was larger than the “noise” VIMP average from RSF.
The final step was a subjective one of reducing the
number of genes to 91, while retaining representation from
each cluster if possible and selecting multiple genes from the
largest clusters if the cluster and the gene appeared to be
strongly associated with survival. A set of 91 genes from 53
clusters were selected.
To compare the relative prediction capability of the
91-gene classifier with the 368-gene classifier based on the
Affymetrix data, we performed the similar RSF prediction
analysis as done with the 368-gene signature described in
Supplementary Results (Supplemental Digital Content 1,
http://links.lww.com/JTO/A115). The 91-gene signature gave
a similar prediction result when compared with using 368
genes with both of the two test sets. The prediction error rates
were 40.7% (33.9% for adenocarcinomas and 43.9% for
SCC) and 36.3%, respectively, for the Bild and Raponi test
sets (Supplementary Table S2, Supplemental Digital Content
2, http://links.lww.com/JTO/A116). This indicated that the
91-gene signature was comparable with the 368-gene signa-
ture in predicting patient survival in lung cancer.
The annotation of the 91 genes is provided in Sup-
plementary Table S3 (Supplemental Digital Content 2,
http://links.lww.com/JTO/A116), and the main biological
categories are indicated in Supplementary Figure S6 (Supple-
mental Digital Content 1, http://links.lww.com/JTO/A115).
Among these, signal transduction, transcription regulation, cell
cycle, cell adhesion, and proliferation are the major biological
processes.
Validation of the 91-Gene Classifier in an
Independent Test Set
To validate the 91-gene classifier for lung cancer prog-
nosis, we used the qRT-PCR card-based platform with a
completely independent cohort of 101 lung adenocarcinomas.
The qRT-PCR data were normalized as described earlier in
the text. The RSF prediction model was built with the 91
genes, tumor stage information, and patient age information
using the average of 20 imputed training sets of 439 tumors.
The qRT-PCR data obtained from the 101 tumors were then
tested with the RSF prediction model. The prediction error
rate for the 101 test cohort was 26.6% (Table 3). We then
tested the usefulness of predictors used to build the RSF using
a univariate Cox model with the MRI as a continuous cova-
riate. The RSF prediction was significant for the 101 patient
cohort (likelihood ratio test [LRT] p  0.00001). Using the
MRI produced from the RSF, three risk groups were also
identified, with patient 5-year survival being significantly
different between low-, medium-, and high-risk groups (haz-
ard ratio 1.00, 2.82, 4.42, p 0.0008; Figure 2A and Table
3). For stage I tumors only, this MRI was also significantly
related to survival (Cox model LRT, p  0.001) and sepa-
rated patients into low-, medium-, and high-risk groups (haz-
ard ratio  1.00, 3.29, 3.78, p  0.04; Figure 2B and Table
3). The area under the curves from receiver operating char-
acteristic analyses were both 0.77 for all patients and for
stage 1 only (Supplementary Figure S7, Supplemental Digital
Content 1, http://links.lww.com/JTO/A115). A notable fea-
ture of the validation shown in Figure 2 is the large separation
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FIGURE 2. Prediction results of the
91-gene quantitative real-time poly-
merase chain reaction (qRT-PCR) sig-
nature in the 101 samples of valida-
tion set. A, Kaplan-Meier survival curve
using patient mortality risk index
(MRI) from the random survival forest
(RSF) prediction model built from
training set including 91 genes, stage,
and age. This predictor could signifi-
cantly separate high-, medium-, and
low-risk groups (one-third in each
group, HR  1.00, 2.82, 4.42, p 
0.0008) among all 101 patients (A),
and among the 59 stage 1 patient
(one-third in each group, HR  1.00,
3.29, 3.776; B).
TABLE 3. Prediction Results of the 91-Gene qRT-PCR
Signature in the Validation set (n  101)
RSFa
Test Error Rate
Cox Modelb
p
Log-Rank Testc
HR 95% CI p
Low risk 26.6% 5.21e-09 1 0.0008
Medium risk 2.82 1.16–6.88
High risk 4.42 1.88–10.42
a RSF prediction model built from 439 training set including 91 genes, stage, and age.
b Mortality risk index (MRI) as continuous value, likelihood ratio test (LRT) was
used, univariate Cox model.
c MRI separated test patients to three risk groups (low, medium, and high risk,
one-third in each group).
qRT-PCR, quantitative real-time polymerase chain reaction; RSF, random survival
forest; HR, hazard ratio; CI, confidence interval.
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between the curves in the first 2 years of follow-up, with
almost no patients dying in the first 2 years for the low-risk
group, but with significant number of deaths in the first 2
years for the high-risk group.
To confirm the MI strategy, we developed results com-
parable with other methods. We built a RSF prediction model
directly from the Affymetrix microarray data of training set
of 439 patients (median centered and MAD scaled) and
applied it to the 101 qRT-PCR validation set (similarly MAD
scaled). We found that the RSF survival prediction results on
the validation set of 101 qRT-PCR patients are similar using
both MI (Table 3 and Figure 2A, Supplemental Digital Con-
tent 1, http://links.lww.com/JTO/A115) and MAD-scaled mi-
croarray data (Supplementary Table S4, Supplemental Digital
Content 2, http://links.lww.com/JTO/A116, and Supplemen-
tary Figure S8, Supplemental Digital Content 1,
http://links.lww.com/JTO/A115) from the training sets of
439 patients.
To evaluate whether the 91-gene set improves the
prediction compared with clinical variables, age, and stage in
the validation set, we compared two Cox models through
LRT; a model with age and stage versus a model with age,
stage, and the mortality index. We found that the set of 91
genes improves the prediction capability when compared
with age and stage only (LRT p  0.0001) using all 101
patients.
We also compared the effect of adjuvant therapy for
these three risk groups defined by the MRI shown in Figure 2A.
We did not observe any benefit from adjuvant therapy in the
high- and medium-risk groups (p 0.8 and 0.5, respectively). A
reduced survival for low-risk patients was observed if adjuvant
therapy was given (p  0.01; Supplementary Fig. S10, Supple-
mental Digital Content 1, http://links.lww.com/JTO/A115).
More detailed results and discussion regarded the effect of
adjuvant therapy are provided in Supplementary Results (Sup-
plemental Digital Content 1, http://links.lww.com/JTO/A115).
DISCUSSION
Lung cancer is a heterogeneous disease, and it is often
difficult to accurately predict patient survival using tumor
pathological characteristics or staging information only. Sev-
eral groups, including ours, have postulated that improved
estimation of an individual patient’s potential risk for recur-
rent disease can be achieved by a combination of clinical
information and certain molecular markers including gene
mutations (e.g., EGFR and KRAS mutations), DNA copy
number change (e.g., MET and IGF1R), and gene or mi-
croRNA expression.24–31 Studies based on gene expression
signatures from microarrays or using qRT-PCR assays have
been reported as predictive of patient survival in lung can-
cer,6–19,32–35 but there is sparse overlap of survival-related
genes from different studies.18 The small amount of gene
overlap may reflect sample collection methods, processing
protocols, single-institutional subject cohorts, statistical
methods, small sample sizes, different analysis platforms, and
different probes used.13,18,36,37 Ein-Dor et al.38 have suggested
that because of biological heterogeneity, thousands of sam-
ples may be required to identify robust and reproducible gene
subsets for most tumor types. Boutros et al.15 demonstrated
that thousands of different six-gene signatures can predict
patient survival if only six genes were used. The largest
microarray-based study of lung adenocarcinomas showed that
combining a cluster and Cox model-based method for gene
selection plus using clinical covariates provided the best
overall survival predictive ability.13 Because the number of
genes in each cluster varied from dozens to hundreds, how-
ever, it would be very difficult to apply some microarray-
based gene classifiers in the clinical setting. These studies
indicate that for an optimal survival classifier, a large sample
size, including more genes in the signature, and appropriate
statistical methods incorporating accurate clinical informa-
tion are needed.39 As an approach, qRT-PCR is a more
reproducible, simple, efficient, and clinical practicable assay.
In this study, we attempted to combine these major criteria to
reduce the number of survival-related genes to a reasonable,
but not necessarily a very small number. Then, we developed
and validated a qRT-PCR card-based 91-gene survival clas-
sifier, using the four major procedures shown in Figure 1, for
the purpose of developing a clinically practicable qRT-PCR-
based assay.
Of the 91 genes in this study, the functional analysis
showed that more than 20 different biological processes were
involved. Most of these processes were cancer related, and
most of these genes have been reported by others as being
involved in cancer development or used for cancer diagno-
sis or prognosis (Supplementary Table S3, Supplemental
Digital Content 2, http://links.lww.com/JTO/A116). We
have compared our 91-gene list with 20 other qRT-PCR-
based or microarray-based studies for lung cancer progno-
sis. Eleven genes were reported also by seven other
studies6,16,19,20,33,40,41(Supplementary Table S5, Supplemental
Digital Content 2, http://links.lww.com/JTO/A116). No over-
lapping genes to this study were reported by the other 13
studies (Supplementary Table S6, Supplemental Digital Con-
tent 2, http://links.lww.com/JTO/A116). Several genes in-
cluding DUSP6 and ERBB3 were also used in Chen et al.16
five-gene signature, and ERBB3 was used in Raz et al.19
four-gene model. SLC2A1 and MEF2C were presented in Lu
et al.33 64-gene profile. Interestingly, five genes were also
reported by Beer et al.6 in 2002.
Gene cluster analysis and a risk index created from Cox
models have been successfully used before as the statistical
approach for gene expression profile-based survival predic-
tion.13 Genes in the same cluster which are coordinately
expressed in a dataset often represent similar biological
functions or define similar pathological features. In our ap-
proach, we specifically chose genes representative of as many
clusters as possible to aid in prediction performance in the
likely case of lung adenocarcinoma tumor heterogeneity. We
used both Cox models and RSF to aid in the identification of
genes and development of the classifier. In general, perfor-
mances of RSF and Cox model were similar, with RSF being
complementary to the Cox model providing genes important
for survival prediction based on the VIMP value.42,43 To our
knowledge, this is the first study to combine clustering, Cox
model, and RSF prediction models for survival-related gene
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selection and then to predict survival from qRT-PCR data in
lung cancer. This is also the first study to impute a large
microarray data to a mimic qRT-PCR value in the training set
in the prediction study and we found a similar performance
(Table 3 and Figure 2) as using Affymetrix microarray-
based values (MAD-scaled) (Supplementary Table S4 and
Supplementary Figure S8, Supplemental Digital Content 1,
http://links.lww.com/JTO/A115).
The strength of this study is that it was prospectively
planned and executed as described in Figure 1. The planned
strategy was of incrementally refining and reducing the num-
ber of genes as the study transitioned from an Affymetrix
platform to a qRT-PCR platform. Another advantage of this
study is the large sample size used in the training set, with the
data being from one uniform study although measured at four
centers. Using the power of imputation, we were able to make
use of the survival data from all 439 subjects in the training
data rather than just the subset of those who had both
Affymetrix and qRT-PCR measurements. We find that the
prediction results using Affymetrix-based measurements us-
ing RSF and the 368 genes were similar to the imputation
method thus supporting its use. Further, the successful sur-
vival prediction for the 91-gene qRT-PCR platform also
included stage 1 cancers. Interestingly, these 91 genes also
can predict patient survival with SCC indicating that some of
the same biological processes may be shared with lung SCC44
and suggesting a greater utility of the prognostic gene set.
The use of prospective clinical trials to test the prediction of
benefit from chemotherapy for patient groups defined by the
MRI are needed to broadly use this classifier for treatment
selection in lung cancer.
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